Posts From July, 2019

Pravin U. Dugel, MD – Kodiak Sciences Announces Upcoming Presentation at American Society of Retina Specialists (ASRS) 2019 Annual Meeting

Initial Phase 1b data for KSI-301 in Wet AMD, DME, and RVO to be presented PALO ALTO, Calif., July 24, 2019 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that data from the ongoing KSI-301 clinical study will be presented… Read More »


Pravin U. Dugel, MD: Patient-Reported Visual Function from Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion, Including Macular Hole (Oasis) Study

In Brief: Symptomatic vitreomacular adhesion is associated with reduced visual acuity, which can significantly affect quality of life. This study was a prespecified analysis of the 2-year, sham-controlled OASIS trial. Clinically meaningful (≥5-point) changes in patient-reported outcomes were assessed. Ocriplasmin resulted in clinically meaningful improvements in visual function. Purpose: To evaluate patient-reported visual function after ocriplasmin… Read More »



Pravin U. Dugel MD: 1,800 Seconds™ in Advances in the Management of Age-Related Macular Degeneration

EARN CREDIT NOW Course Director: Pravin U. Dugel, MD Release Date: March 31, 2019 Expiration Date: March 31, 2020 Credits Available: Physicians – maximum of 0.5 AMA PRA Category 1 Credits™ Jointly provided by Postgraduate Institute for Medicine and Catamount Medical Education Supported by an independent educational grant from Novartis Pharmaceuticals Corporation Release Date: March… Read More »


Dr. Pravin U. Dugel: Oxurion NV Reports Positive Topline Phase 1 Results with THR-149

Oxurion NV Reports Positive Topline Phase 1 Results with THR-149, a novel, potent plasma kallikrein inhibitor for the treatment of DME Topline data show that THR-149 is well-tolerated and safe. No dose-limiting toxicities or drug-related serious adverse events reported. Rapid onset of action starting at Day 1 with increasing average improvement in Best Corrected Visual… Read More »